IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc.

IDYANYSE / NASDAQHealthcareSmall cap

$25.56-$0.61 (-2.3%)

Last close · Data as of Nov 20, 2026

Market cap
$2.6B
P/E
-22.6x
EV / EBITDA
-16.0x
Revenue
$218.7M
Net margin
-52.0%
ROCE
-15.2%

-22.9% over the last year

IDEAYA Biosciences, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-27.7%
3M
-34.6%
6M
-13.8%
1Y
-22.9%
5Y
+10.1%

52-week range

Day change -$0.61 (-2.3%) from $26 to $26 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in IDYA, bought on each weekday since 2021.

News & filings

What IDEAYA Biosciences filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 114 million US dollars in fiscal 2025.

Strengths (1)

  • Revenue more than doubled in fiscal 2025.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.

Read moreShow less

IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer driven by GNAQ/11 mutations, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor that is in a Phase 1 clinical trial for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 dose optimization trial; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. It also has a clinical collaboration agreement with AstraZeneca plc to evaluate the efficacy and safety of IDE849, an antibody-drug conjugate. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Sector
Healthcare
Shares outstanding
87.8M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$2.6B
P/E
-22.6x
P/B
2.5x
EV / EBITDA
-16.0x
EV / Sales
11.4x
P/S
11.7x
52-week high
$42.48
52-week low
$25.56

Profitability

Operating margin
-72.8%
Net margin
-52.0%
EBITDA margin
-70.7%
ROE
-11.1%
ROCE
-15.2%
ROIC
-13.4%
ROA
-10.2%
Asset turnover
0.20

Growth

Revenue
$218.7M
Revenue growth, 1Y
3024.4%
Revenue CAGR, 3Y
62.5%
Net profit growth, 1Y
-58.6%
Free cash flow
-$73.5M

Solvency

Current ratio
11.34
Debt / Equity
0.03
Debt / Assets
0.03
CFO / Net profit
0.63
Cash / Market cap
4.4%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$218.7M
Gross profit$218.7M
Operating expenses$378.0M
Research and development$314.7M
Selling, general and administrative$63.3M
Operating income-$159.3M
Interest and other$45.6M
Pretax income-$113.7M
Tax and other$0.00
Net income-$113.7M

Revenue and net profit

Revenue grew 3024.4% in FY2025; net profit is the dashed line.

IDEAYA Biosciences, Inc. revenue and net profit by fiscal year
IDEAYA Biosciences, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$50.9M-$58.7M
FY2023$23.4M-$113.0M
FY2024$7.0M-$274.5M
FY2025$218.7M-$113.7M

Cash flows

FY2025: -$71.1M from operations, -$73.5M free after investment (dashed).

IDEAYA Biosciences, Inc. operating and free cash flow by fiscal year
IDEAYA Biosciences, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$87.2M-$90.6M
FY2023-$115.2M-$117.6M
FY2024-$247.6M-$251.4M
FY2025-$71.1M-$73.5M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$218.7M+3,024.4%1Y
EBITDA
-$154.7M
Net profit
-$113.7M
Cash from operations
-$71.1M
Free cash flow
-$73.5M
Revenue CAGR, 3Y
62.5%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$218.7M-$154.7M-$113.7M-$73.5M-11.1%+3024.4%-58.6%

Monthly returns

Month-by-month returns of IDYA across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$1.1B
Liabilities$86.4M
Equity$1.0B
Paid-in capital$1.8B
Retained earnings-$736.5M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; IDYA highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. IDEAYA Biosciences, Inc. (this company)11.4x

Not shown (no positive earnings and no EV / Sales): Disc Medicine, Inc., Definium Therapeutics, Inc., Vera Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
IDEAYA Biosciences, Inc.IDYAthis company$2.6B-22.6x2.5x-11.1%-16.0x
Arcutis Biotherapeutics, Inc.ARQT$2.7B-170.1x14.5x-8.5%1582.5x
Disc Medicine, Inc.IRON$2.7B-12.8x3.7x-28.7%-12.8x
Definium Therapeutics, Inc.DFTX$2.7B-14.6x8.1x-55.3%-13.8x
Alumis Inc.ALMS$2.6B-10.7x8.6x-80.8%-5.7x
Tarsus Pharmaceuticals, Inc.TARS$2.6B-39.1x7.6x-19.3%-45.8x
Guardian Pharmacy Services, Inc.GRDN$2.6B52.5x12.6x23.9%26.5x
Heartflow, Inc.HTFL$2.5B-21.3x8.3x-38.8%-26.4x
Vera Therapeutics, Inc.VERA$2.4B-8.0x4.0x-49.6%-7.3x
Peer median—-13.7x8.2x-33.8%-10.0x

Year-to-date ROI

IDYA since 1 January, against earlier years.

Historical volatility

IDYA's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

IDEAYA Biosciences, Inc. operating margin by fiscal year
IDEAYA Biosciences, Inc. operating margin by fiscal year
DateOperating margin
FY2022-122.7%
FY2023-575.0%
FY2024-4671.1%
FY2025-72.8%
LineFY2025
Operating expensesOperating Expense$378.0M
Research and developmentResearch And Development$314.7M
Total expensesTotal Expenses$378.0M
Pretax incomePretax Income-$113.7M

Learn while you research

Academy chapters picked for IDEAYA Biosciences, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing3024% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →